Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
Berge
Maud
M
Université Paris Descartes, Paris, France.
Guillemain
Romain
R
Trégouet
David A
DA
Amrein
Catherine
C
Boussaud
Veronique
V
Chevalier
Patrick
P
Lillo-Lelouet
Agnes
A
Le Beller
Christine
C
Laurent-Puig
Pierre
P
Beaune
Philippe H
PH
Billaud
Eliane M
EM
Loriot
Marie-Anne
MA
D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D001228:Aspergillosis / Q000188:drug therapy / Q000209:etiology; D003550:Cystic Fibrosis / Q000150:complications; D065731:Cytochrome P-450 CYP2C19; D004305:Dose-Response Relationship, Drug; D005260:Female; D005838:Genotype; D006801:Humans; D016040:Lung Transplantation; D008297:Male; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D012189:Retrospective Studies; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D065819:Voriconazole; D055815:Young Adult
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D065819:Voriconazole